To explore whether the combination of mTORi has a positive impact on generating more potent anti-tumor effects of CTGF/E7 DNA vaccine, various inhibitors of mTOR were used for in vivo tumor treatment via various therapeutic protocols (Figure 7A). The gene discussed is CCN2; the disease is neoplasm.